drugset / Trial / NCT07049055
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Phase 1/2
Recruiting
144 enrolled
Engeneic Pty Limited
Herbert Irving Comprehensive Cancer Center · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Timeline
- Start
- 2026-01-12
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E-EDV-D682 | Other / unclassified | — | Intravenous |
| Subject | EDV-GC | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |